Churg-Strauss syndrome risk factors

	Churg-Strauss syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Churg-Strauss syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Churg-Strauss syndrome risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Churg-Strauss syndrome risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Churg-Strauss syndrome risk factors
CDC on Churg-Strauss syndrome risk factors
Churg-Strauss syndrome risk factors in the news
Blogs on Churg-Strauss syndrome risk factors
Directions to Hospitals Treating Churg-Strauss syndrome
Risk calculators and risk factors for Churg-Strauss syndrome risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]

Overview

There are no established risk factors for eosinophilic granulomatosis with polyangiitis. However, certain environmental agents including various allergens, infections, desensitization, vaccination, and genetics may act as triggering agents. Those triggers may be responsible for the inflammatory response with eosinophils and lymphocytes.

Common risk factors in the development of eosinophilic granulomatosis with polyangiitis may be various allergens, infections, genetic factors, and desensitization to drugs and vaccinations.

Genetic determinants:^[1]^[2]
- HLA-DRB1*04 AND *07
- HLA-DRB4
- Interleukin 10 gene single nucleotide polymorphisms
Allergic agents
Infections
Vaccination
Exposure to silica
Drugs:^[3]^[4]^[5]
- Leukotriene receptor antagonists (eg, montelukast, zafirlukast)
- Anti-IgE antibody (eg,omalizumab)
- Cocaine
- Inhaled glucocorticoids
- Mesalazine
- Propylthiouracil
- Methimazole

↑ Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, Garini G, Manganelli P, Bottero P, Tumiati B, Sinico RA, Savi M, Buzio C, Neri TM (September 2007). "HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome". Arthritis Rheum. 56 (9): 3159–66. doi:10.1002/art.22834. PMID 17763415.
↑ Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT (June 2008). "Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis". Arthritis Rheum. 58 (6): 1839–48. doi:10.1002/art.23496. PMID 18512809.
↑ Puéchal X, Rivereau P, Vinchon F (July 2008). "Churg-Strauss syndrome associated with omalizumab". Eur. J. Intern. Med. 19 (5): 364–6. doi:10.1016/j.ejim.2007.09.001. PMID 18549941.
↑ Gómez-Puerta JA, Gedmintas L, Costenbader KH (October 2013). "The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis". Autoimmun Rev. 12 (12): 1129–35. doi:10.1016/j.autrev.2013.06.016. PMC 4086751. PMID 23820041.
↑ Orriols R, Muñoz X, Ferrer J, Huget P, Morell F (January 1996). "Cocaine-induced Churg-Strauss vasculitis". Eur. Respir. J. 9 (1): 175–7. PMID 8834352.